Randomized, open-label phase II study evaluating the safety and efficacy of Cetuximab plus modified FOLFOX - 6 versus modified FOLFOX - 6 alone as 2nd line therapy after progression on the 1st line treatment with Cetuximab + FOLFIRI in patients with metastatic colorectal cancer KRAS wild-type-TAGUS Study.
Phase of Trial: Phase II
Latest Information Update: 11 Jul 2012
At a glance
- Drugs Cetuximab; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms TAGUS
- 11 Jul 2012 Merck KGaA added as associations as reported in the European Clinical Trials Database record.
- 15 Mar 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
- 02 Aug 2011 New trial record